Evidence map›Paper›PMID 33845763›Full record

ArticleBMC bioinformatics2021

Application of network link prediction in drug discovery.

Khushnood Abbas, Alireza Abbasi, Shi Dong, Ling Niu, Laihang Yu, Bolun Chen, Shi-Min Cai, Qambar Hasan

Abstract read
In one paragraph

Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Drug-disease networks and drug repurposing.PLoS computational biology · 2025
    Article
  6. Article
  7. Article
  8. Measuring drug similarity using drug-drug interactions.Quantitative biology (Beijing, China) · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. CompositeView: A Network-Based Visualization Tool.Big data and cognitive computing · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Link Prediction in Multipartite Graphs With Application to Drug Repositioning Studies.IEEE transactions on computational biology and bioinformatics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Khushnood AbbasSchool of Computer Science and Technology, Zhoukou Normal University, Zhoukou, 466001, China. abbas@cigit.ac.cn.ORCID http://orcid.org/0000-0002-0096-3179
Alireza AbbasiSchool of Engineering and Information Technology, University of New South Wales, Canberra, NSW, 2006, Australia.
Shi DongSchool of Computer Science and Technology, Zhoukou Normal University, Zhoukou, 466001, China.
Ling NiuSchool of Computer Science and Technology, Zhoukou Normal University, Zhoukou, 466001, China.
Laihang YuSchool of Computer Science and Technology, Zhoukou Normal University, Zhoukou, 466001, China.
Bolun ChenCollege of Computer and Software Engineering, Huaiyin Institute of Technology, Huaian, 223003, China.
Shi-Min CaiSchool of Computer Science and Engineering, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Qambar HasanCentre for Cellular and Molecular Biology, School of Life and Environmental Science, Deakin University, Burwood, VIC, 3125, Australia.

Funding

http://dx.doi.org/10.13039/501100011447 202102210379Zhoukou Normal University ZKNUC2018019
6 · The paper itself

Abstract

backgroundTechnological and research advances have produced large volumes of biomedical data. When represented as a network (graph), these data become useful for modeling entities and interactions in biological and similar complex systems. In the field of network biology and network medicine, there is a particular interest in predicting results from drug-drug, drug-disease, and protein-protein interactions to advance the speed of drug discovery. Existing data and modern computational methods allow to identify potentially beneficial and harmful interactions, and therefore, narrow drug trials ahead of actual clinical trials. Such automated data-driven investigation relies on machine learning techniques. However, traditional machine learning approaches require extensive preprocessing of the data that makes them impractical for large datasets. This study presents wide range of machine learning methods for predicting outcomes from biomedical interactions and evaluates the performance of the traditional methods with more recent network-based approaches.

resultsWe applied a wide range of 32 different network-based machine learning models to five commonly available biomedical datasets, and evaluated their performance based on three important evaluations metrics namely AUROC, AUPR, and F1-score. We achieved this by converting link prediction problem as binary classification problem. In order to achieve this we have considered the existing links as positive example and randomly sampled negative examples from non-existant set. After experimental evaluation we found that Prone, ACT and [Formula: see text] are the top 3 best performers on all five datasets.

conclusionsThis work presents a comparative evaluation of network-based machine learning algorithms for predicting network links, with applications in the prediction of drug-target and drug-drug interactions, and applied well known network-based machine learning methods. Our work is helpful in guiding researchers in the appropriate selection of machine learning methods for pharmaceutical tasks.

Indexed as

Drug DiscoveryMachine LearningAlgorithmsDrug InteractionsData-driven drug discoveryDrug-target predictionNetwork link predictionPoly-pharmacyPoly-pharmacy side effects prediction

Identifiers

PMID33845763
PMCPMC8042985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.